RayKnowChina Research Map
Shortlist

ZhengzhouZhengzhou University

First Affiliated Hospital of Zhengzhou University

郑州大学第一附属医院

Listed for 39 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Zhengzhou University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌15 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌79 papers led6 open trials led
  3. Hepatocellular carcinoma肝细胞癌169 papers led2 open trials led
  4. Stomach cancer胃癌105 papers led5 open trials led
  5. Hepatoblastoma肝母细胞瘤2 papers led
  6. Retinoblastoma视网膜母细胞瘤5 papers led
  7. Chordoma脊索瘤0 papers led
  8. Osteosarcoma骨肉瘤34 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤8 papers led
  10. Neuroblastoma神经母细胞瘤15 papers led
  11. Ewing sarcoma尤文肉瘤3 papers led
  12. Multiple myeloma多发性骨髓瘤15 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led1 open trial led
  14. Aplastic anaemia再生障碍性贫血9 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症3 papers led
  16. Beta thalassaemiaβ 地中海贫血0 papers led
  17. Haemophilia A血友病 A3 papers led
  18. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  19. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病11 papers led
  20. Myasthenia gravis重症肌无力4 papers led
  21. Moyamoya disease烟雾病10 papers led
  22. Wilson disease肝豆状核变性(Wilson 病)1 paper led
  23. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎9 papers led
  24. Takayasu arteritis大动脉炎0 papers led
  25. Hepatic echinococcosis肝包虫病1 paper led
  26. Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
  27. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  28. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  29. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  30. Fabry disease法布雷病0 papers led
  31. Pompe disease庞贝病0 papers led
  32. Duchenne muscular dystrophy杜氏肌营养不良6 papers led
  33. Behçet disease白塞病9 papers led
  34. Alport syndromeAlport 综合征0 papers led
  35. IgA nephropathyIgA 肾病35 papers led
  36. Osteogenesis imperfecta成骨不全症0 papers led
  37. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  38. Hirschsprung disease先天性巨结肠0 papers led
  39. Leber hereditary optic neuropathyLeber 遗传性视神经病变2 papers led

Not listed for: Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Biliary atresia, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 15 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 5520222023: 3320232024: 3320242025: 222025

4 hospitals in Zhengzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyRadiotherapy techniqueSide effects & quality of life
Departments in papersRadiation oncologyENT / head & neck surgeryPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. Alterations in nasal airflow and air conditioning after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: a pilot computational fluid dynamics study.2026Computer methods in biomechanics and biomedical engineering
  2. Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.2025Annals of medicineFree full text
  3. The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.2025PloS oneFree full text
  4. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer.2024Cancer medicineFree full text
  5. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.2024Histology and histopathology
  6. How enteral nutrition modes influence nasopharyngeal carcinoma survivors with late dysphagia after radiotherapy: a randomized controlled study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  7. The role of extracellular vesicles in the development of nasopharyngeal carcinoma and potential clinical applications.2023Cancer medicineFree full text
  8. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.2023Cell cycle (Georgetown, Tex.)Free full text
  9. CircMAN1A2 contributes to nasopharyngeal carcinoma progression via enhancing the ubiquitination of ATMIN through miR-135a-3p/UBR5 axis.2023Human cell
  10. Tumor cell-derived exosome RNF126 affects the immune microenvironment and promotes nasopharyngeal carcinoma progression by regulating PTEN ubiquitination.2022Apoptosis : an international journal on programmed cell death
  11. Differentially Infiltrated Identification of Novel Diagnostic Biomarkers Associated with Immune Infiltration in Nasopharyngeal Carcinoma.2022Disease markersFree full text
  12. miR-339-3p inhibits cell growth and epithelial-mesenchymal transition in nasopharyngeal carcinoma by modulating the KAT6A/TRIM24 axis.2022International journal of clinical oncology
  13. Hyperthermia inhibits growth of nasopharyngeal carcinoma through degradation of c-Myc.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  14. Circular RNA ITCH attenuates the progression of nasopharyngeal carcinoma by inducing PTEN upregulation via miR-214.2022The journal of gene medicine
  15. Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.2021Experimental & molecular medicineFree full text
Chinese-language papers (not in the count)1
  1. [Nasopharyngeal carcinoma with non-squamous immunophenotype: a clinicopathological analysis of 23 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status1
  1. Health Outcomes of Nasopharyngeal Carcinoma Patients Three Years After Treatment by the AI-assisted Home Enteral Nutrition ManagementCompletedNCT06603909Study siteN/AStart 2021-01
More papers found outside PubMed (not counted)7
  1. Genistein and chlorin E6-loaded versatile nanoformulation for remodeling the hypoxia-related tumor microenvironment and boosting photodynamic therapy in nasopharyngeal carcinoma treatment2025Advanced Composites and Hybrid Materialsarticle
  2. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)preprint
  3. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  4. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figsharedataset
  5. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  6. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract
  7. Retraction Note: MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by downregulating LHX22021Journal of Experimental & Clinical Cancer Researchretraction

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 79 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.7%.

Papers led
79
2021–2025
Trials led
18
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 131320212022: 232320222023: 101020232024: 151520242025: 18182025

6 hospitals in Zhengzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT07016724

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  2. Recruiting
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05738434

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  3. Recruiting
    Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06718205

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  4. Recruiting
    A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05182944

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  5. Not yet recruiting
    A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07446335

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  6. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

  7. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  8. Recruiting
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07751341

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyNeoadjuvant & combined treatment
Departments in papersPathology / laboratory medicineMedical oncologyRadiation oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led79
  1. Comparison of single-port inflatable mediastinoscopic esophagectomy and thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.2025BMC cancerFree full text
  2. Oridonin combined with cisplatin synergistically induces apoptosis by activating the NOXA-BCL2 axis in esophageal squamous cell carcinoma.2025Biochemical pharmacology
  3. Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  4. SETD7-mediated H3K4me1 activates ALDH1A3 to drive ferroptosis resistance in esophageal squamous cell carcinoma.2025Cell death & diseaseFree full text
  5. CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1.2025Cellular & molecular biology lettersFree full text
  6. NDC80 promotes epithelial to mesenchymal transition of esophageal squamous cell carcinoma through macrophages polarization and PI3K/AKT pathway activation.2025European journal of medical researchFree full text
  7. Identification of CTSC-driven progression in ESCC by single-cell sequencing and experimental validation.2025Frontiers in immunologyFree full text
  8. TGF-β-activated NK-92 cell therapy for esophageal squamous cell carcinoma.2025International immunopharmacology
  9. Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.2025Molecular cancerFree full text
  10. GPR87 Promotes Angiogenesis in Esophageal Squamous Cell Carcinoma via VEGFA Regulation.2025Molecular carcinogenesis
  11. LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K-AKT-mTOR Signaling Pathway by Interacting With IGF2BP2.2025Molecular carcinogenesis
  12. FKBP Prolyl Isomerase 11: A Novel Oncogene Interacting With SRSF1 in Esophageal Squamous Cell Carcinoma.2025Molecular carcinogenesis
  13. Triptolide reverses cis‑diamminedichloroplatinum resistance in esophageal squamous cell carcinoma by suppressing glycolysis and causing mitochondrial malfunction.2025Molecular medicine reportsFree full text
  14. Targeting CDH11 with celecoxib and derivatives to suppress esophageal squamous cell carcinoma proliferation and invasion.2025Pathology, research and practice
  15. Dynamic landscape and regulation of m5C methylation in human tissues.2025Science China. Life sciences
  16. Survival Outcome of Thoraco-Laparoscopic McKeown Esophagectomy Versus Endoscopic Submucosal Dissection for Early-Stage Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.2025Thoracic cancer
  17. Ethnic genomic differences in esophageal squamous cell carcinoma: Whole-exome sequencing of Han and Kazakh populations in China.2025World journal of gastroenterologyFree full text
  18. Circ_0001741 regulates proliferation and invasion in ESCC via the miR-194-5p/E2F3 axis.2025World journal of surgical oncologyFree full text
  19. [Not Available].2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  20. PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.2024Biology directFree full text
  21. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.2024Bioorganic chemistry
  22. Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test.2024British journal of cancerFree full text
  23. A 18F-FDG PET/CT-based deep learning-radiomics-clinical model for prediction of cervical lymph node metastasis in esophageal squamous cell carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  24. Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1+ macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  25. A 70-Year-Old Man With an Encapsulated Mediastinal Fluid Collection.2024Chest
  26. Construction and analysis of protein-protein interaction network for esophageal squamous cell carcinoma.2024Computers in biology and medicine
  27. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.2024European journal of cancer (Oxford, England : 1990)
  28. Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis.2024Frontiers in immunologyFree full text
  29. A novel link between circPDE3B and ferroptosis in esophageal squamous cell carcinoma progression.2024Genomics
  30. Exosome-transported of circ_0081069 induces SPIN1 production by binding to miR-195-5p to inhibit radiosensitivity in esophageal squamous cell carcinoma.2024Journal of biochemical and molecular toxicology
  31. Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study.2024Med (New York, N.Y.)
  32. The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma.2024Nature communicationsFree full text
  33. Clinical and genetic characteristics of patients with TRG 0 and TRG III in esophageal squamous cell carcinoma after neoadjuvant therapy.2024Scientific reportsFree full text
  34. STAT3-EphA7 axis contributes to the progression of esophageal squamous cell carcinoma.2023Acta oncologica (Stockholm, Sweden)
  35. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  36. Downregulation of miR-100-5p in cancer-associated fibroblast-derived exosomes facilitates lymphangiogenesis in esophageal squamous cell carcinoma.2023Cancer medicineFree full text
  37. USP8 inhibitor-induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma.2023Cell biology and toxicology
  38. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.2023Frontiers in immunologyFree full text
  39. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.2023Frontiers in immunologyFree full text
  40. Integration of IDPC Clustering Analysis and Interpretable Machine Learning for Survival Risk Prediction of Patients with ESCC.2023Interdisciplinary sciences, computational life sciences
  41. Long non-coding RNA HOXC-AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression.2023Journal of clinical laboratory analysisFree full text
  42. G2 and S phase-expressed-1 induces chromosomal instability in esophageal squamous cell carcinoma cells and inhibits cell apoptosis through ROS/JNK signaling.2023Molecular carcinogenesis
  43. Expression significance of Emi1, UBCH10 and CyclinB1 in esophageal squamous cell carcinoma.2023Pathology oncology research : PORFree full text
  44. Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A.2022Analytical cellular pathology (Amsterdam)Free full text
  45. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.2022Anti-cancer drugsFree full text
  46. ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells.2022Apoptosis : an international journal on programmed cell death
  47. Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway.2022Applied biochemistry and biotechnology
  48. Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection.2022BMC medical genomicsFree full text
  49. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial.2022BMJ openRCTFree full text
  50. Long non-coding RNA NCK1-AS1 is overexpressed in esophageal squamous cell carcinoma and predicts survival.2022BioengineeredFree full text
  51. Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14.2022BioengineeredFree full text
  52. Similarities between wound re-epithelialization and Metastasis in ESCC and the crucial involvement of macrophages: A review.2022Cancer treatment and research communications
  53. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.2022Clinics and research in hepatology and gastroenterology
  54. Survival Prediction Model for Patients with Esophageal Squamous Cell Carcinoma Based on the Parameter-Optimized Deep Belief Network Using the Improved Archimedes Optimization Algorithm.2022Computational and mathematical methods in medicineFree full text
  55. Survival Risk Prediction of Esophageal Squamous Cell Carcinoma Based on BES-LSSVM.2022Computational intelligence and neuroscienceFree full text
  56. Survival risk prediction model for ESCC based on relief feature selection and CNN.2022Computers in biology and medicine
  57. Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.2022Cytotherapy
  58. Immuno-oncological role of 20S proteasome alpha-subunit 3 in aggravating the progression of esophageal squamous cell carcinoma.2022European journal of immunology
  59. Long non-coding RNA BBOX1-AS1 exacerbates esophageal squamous cell carcinoma development by regulating HOXB7/β-catenin axis.2022Experimental cell research
  60. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.2022Frontiers in immunologyFree full text
  61. Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma.2022Journal of cellular and molecular medicineFree full text
  62. IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis.2022Journal of experimental & clinical cancer research : CRFree full text
  63. Serine 727 phosphorylation is necessary to induce the STAT3-mediated transcription of LINC00184 in oesophageal squamous cell carcinoma.2022Molecular and cellular biochemistry
  64. Antitumor Effects of Astaxanthin on Esophageal Squamous Cell Carcinoma by up-Regulation of PPARγ.2022Nutrition and cancer
  65. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.2022The lancet. Gastroenterology & hepatology
  66. Increased prognostic value of clinical-reproductive model in Chinese female patients with esophageal squamous cell carcinoma.2022World journal of gastroenterologyFree full text
  67. Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.2021AgingFree full text
  68. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.2021Cancer letters
  69. Eomes promotes esophageal carcinoma progression by recruiting Treg cells through the CCL20-CCR6 pathway.2021Cancer scienceFree full text
  70. Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression.2021Cell death & diseaseFree full text
  71. Inhibition of deubiquitination by PR-619 induces apoptosis and autophagy via ubi-protein aggregation-activated ER stress in oesophageal squamous cell carcinoma.2021Cell proliferationFree full text
  72. High serum superoxide dismutase activity improves radiation-related quality of life in patients with esophageal squamous cell carcinoma.2021Clinics (Sao Paulo, Brazil)Free full text
  73. Concomitant Expression of Inhibitory Molecules for T cell Activation Predicts Poor Survival in Patients with Esophageal Squamous Cell Carcinoma.2021Current cancer drug targets
  74. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.2021International immunopharmacology
  75. LINC00514 promotes lipogenesis and tumor progression in esophageal squamous cell carcinoma by sponging miR‑378a‑5p to enhance SPHK1 expression.2021International journal of oncologyFree full text
  76. TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.2021Journal of experimental & clinical cancer research : CRFree full text
  77. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Esophageal Squamous Cell Carcinoma Patients.2021Nutrition and cancer
  78. Long non‑coding RNA CASC15 facilitates esophageal squamous cell carcinoma tumorigenesis via decreasing SIM2 stability via FTO‑mediated demethylation.2021Oncology reportsFree full text
  79. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)5
  1. [Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies].2023Zhongguo shi yan xue ye xue za zhiRCT
  2. [Study on the prognostic influencing factors of esophageal squamous cell carcinoma and the predictive value of inflammatory reaction indexes on its postoperative recurrence].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Clinical characteristics of 272 437 patients with different histopathological subtypes of primary esophageal malignant tumors].2022Zhonghua nei ke za zhi
  4. [The suppressive effects of microRNA-139-5p on proliferation and invasion of esophageal squamous cell carcinoma].2021Zhonghua yi xue za zhi
  5. [Establishment and validation of prognostic risk score model for esophageal squamous cell carcinoma based on immune related genes].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status36
  1. A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07446335Lead sponsorPhase 3Start 2026-04
  2. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Lead sponsorStart 2026-09
  3. Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell CancerRecruitingNCT07016724Lead sponsorPhase 2Start 2024-08
  4. Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Lead sponsorPhase 2Start 2023-03
  5. Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCCRecruitingNCT05738434Lead sponsorPhase 2Start 2023-03
  6. A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCCRecruitingNCT05182944Lead sponsorPhase 2Start 2022-01
  7. IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Status unknownNCT06078657Lead sponsorPhase 2Start 2023-10
  8. Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT05896787Lead sponsorPhase 2Start 2023-08
  9. Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell CancerStatus unknownNCT04654403Lead sponsorN/AStart 2022-01
  10. Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Status unknownNCT05038813Lead sponsorPhase 2Start 2022-03
  11. Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03766178Lead sponsorPhase 2Start 2021-09
  12. A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCStatus unknownNCT04514835Lead sponsorPhase 2Start 2021-12
  13. Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04888403Lead sponsorPhase 2Start 2021-12
  14. The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Lead sponsorPhase 2Start 2020-04
  15. A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03736863Lead sponsorPhase 2Start 2019-12
  16. Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaStatus unknownNCT03387904Lead sponsorPhase 2Start 2019-01
  17. A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCStatus unknownNCT03817658Lead sponsorPhase 2Start 2019-10
  18. Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03193424Lead sponsorPhase 2Start 2016-10
  19. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  20. A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07751341Study sitePhase 2Start 2026-09
  21. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  22. Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedNCT05834543Study sitePhase 1/Phase 2Start 2023-05
  23. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  24. Clinical Study of Pan-cancer DNA Methylation Test in PlasmaStatus unknownNCT05685524Study siteStart 2022-07
  25. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  26. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  27. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  28. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  29. A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Study sitePhase 3Start 2019-06
  30. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  31. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  32. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  33. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  34. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  35. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12
  36. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)72
  1. 022. TREATMENT EXPERIENCE OF ESOPHAGEAL FISTULA INDUCED BY NEOADJUVANT THERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-CENTER EXPERIENCE2025Diseases of the Esophagusarticle
  2. 023. CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY FOLLOWED BY SALVAGE LYMPHADENECTOMY FOR RECURRENCE IN CERVICAL LYMPH NODES AFTER ESOPHAGECTOMY: A SINGLE-CENTER PROSPECTIVE STUDY2025Diseases of the Esophagusarticle
  3. 024. CONVERSION ESOPHAGECTOMY FOLLOWING IMMUNOCHEMOTHERAPY IN UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-CENTER, PROSPECTIVE STUDY2025Diseases of the Esophagusarticle
  4. 2131P Adebrelimab plus apatinib in advanced esophageal squamous cell carcinoma following immune checkpoint inhibitors: Preliminary results from cohort 3 of CAP 02 study2025Annals of Oncologyarticle
  5. Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2025Journal of Clinical Oncologyconference-abstract
  6. Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.2025Journal of Clinical Oncologyarticle
  7. Functional characterization of GNA11 in esophageal squamous cell carcinoma: bioinformatics and cellular functional analysis2025ScienceAsiaarticle
  8. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Squarepreprint
  9. 442. POSTOPERATIVE ADJUVANT RADIOTHERAPY REDUCES LOCOREGIONAL RECURRENCE IN PATIENTS WITH BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagusarticle
  10. 448. PREOPERATIVE PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY FOR THORACIC ESCC WITH CERVICAL LYMPH NODE METASTASIS (PICC-1): A PROSPECTIVE, PHASE 2 STUDY2024Diseases of the Esophagusarticle
  11. 502P A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: A multicenter study in China2024Annals of Oncologyarticle
  12. A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.2024Journal of Clinical Oncologyconference-abstract
  13. A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  14. Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  15. Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  16. Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.2024Journal of Clinical Oncologyconference-abstract
  17. Clinical pathological characteristics and expression of 328 proteins and their impact on survival in over 20,000 cases of esophageal squamous cell carcinoma and colorectal adenocarcinoma2024Chinese Science Bulletin (Chinese Version)article
  18. Development of a new EGFR-VHH-CAR T-cell therapy for treatment of esophageal squamous cell carcinoma2024Research Squarepreprint
  19. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  20. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncologyconference-abstract
  21. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  22. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncologyconference-abstract
  23. Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  24. Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  25. 1531P Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial2023Annals of Oncologyarticle
  26. 482. SECOND-LINE OF CAMRELIZUMAB PLUS NIMOTUZUMAB IN ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A SINGLE-ARM, OPEN-LABEL, PHASE 2 TRIAL2023Diseases of the Esophagusarticle
  27. 487. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2023Diseases of the Esophagusarticle
  28. A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.2023Journal of Clinical Oncologyconference-abstract
  29. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  30. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  31. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  32. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  33. Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2023Journal of Clinical Oncologyconference-abstract
  34. Anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer: Updated results from a retrospective real-world study.2023Journal of Clinical Oncologyconference-abstract
  35. Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.2023Journal of Clinical Oncologyconference-abstract
  36. Data from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers2023Venue not listedother
  37. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncologyconference-abstract
  38. Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.2023Journal of Clinical Oncologyconference-abstract
  39. Survival Prediction of Esophageal Squamous Cell Carcinoma Based on the Prognostic Index and Sparrow Search Algorithm-Support Vector Machine2023Current Bioinformaticsarticle
  40. Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.2023Journal of Clinical Oncologyconference-abstract
  41. 345. CAMRELIZUMAB AS ADJUVANT THERAPY IN RESECTED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2022Diseases of the Esophagusarticle
  42. 355. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2022Diseases of the Esophagusarticle
  43. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  44. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  45. Analysis of the crosstalk between EMT-related gene and Tumor-infiltrating immune cell in Esophageal Squamous Cell Carcinoma2022Research Squarepreprint
  46. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  47. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  48. Prediction of Postoperative Survival Level of Esophageal Cancer Patients Based on Kaplan-Meier (K-M) Survival Analysis and Gray Wolf Optimization (GsWO)-BP Model2022Communications in computer and information scienceconference-paper
  49. Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)2022Research Squarepreprint
  50. Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  51. 151 A RANDOMIZED,OPEN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ANLOTINIB PLUS IRINOTECAN VERSUS IRINOTECAN IN PATIENTS WITH ESCC2021Diseases of the Esophagusarticle
  52. 155 A META-ANALYSIS OF EFFICACY AND SAFETY OF ANTI-BODIES TARGETING PD-1 IN TREATMENT OF ADVANCED ESOPHAGEAL CANCER2021Diseases of the Esophagusreview
  53. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  54. 159 METFORMIN DOWNREGULATES PD-L1 EXPRESSION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY INHIBITING IL-6 SIGNALING PATHWAY2021Diseases of the Esophagusarticle
  55. 659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  56. 740 CAMRELIZUMAB IN COMBINATION WITH PREOPERATIVE CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY2021Diseases of the Esophagusarticle
  57. Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncologyconference-abstract
  58. Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncologyconference-abstract
  59. Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncologyconference-abstract
  60. Correction to: Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression2021Journal of Experimental & Clinical Cancer Researcherratum
  61. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  62. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  63. Identify risk factors and predict the postoperative risk of ESCC using ensemble learning2021Biomedical Signal Processing and Controlarticle
  64. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Squarepreprint
  65. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  66. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  67. LncRNA NCK1-AS1 is overexpressed in esophageal squamous cell carcinoma and predicts survival2021Research Squarepreprint
  68. Preliminary Study on the Role and Mechanism of KIRREL3 in the Development of Esophageal Squamous Cell Carcinoma (ESCC)2021Research Squarepreprint
  69. Progress of Exosome in the Pathogenesis, Diagnosis and Treatment of Esophageal Squamous Cell Carcinoma2021Cancer Cell Researcharticle
  70. The Efficacy and Safety of Anti-bodies Targeting PD-1 for Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-analysis2021Research Squarepreprint
  71. The anticancer effects of Levonorgestrel on human esophageal squamous carcinoma cells2021Research Squarepreprint
  72. [Retracted] HNF1A‑AS1 promotes growth and metastasis of esophageal squamous cell carcinoma by sponging miR‑214 to upregulate the expression of SOX-42021International Journal of Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 169 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
169
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
11
led by another institution
Papers led per year
2021: 323220212022: 464620222023: 353520232024: 333320242025: 19192025

3 hospitals in Zhengzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
    Phase
    Phase 4
    Started
    2024-12
    Registry
    NCT06930573

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  2. Not yet recruiting
    A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
    Phase
    Phase 4
    Started
    2026-08
    Registry
    NCT07790419

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  3. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  4. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

  6. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  8. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  9. Recruiting
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05155189

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou

  10. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  11. Not yet recruiting
    A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06823050

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  12. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  13. Not yet recruiting
    A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07156617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyPathology / laboratory medicine
Papers it led169
  1. EMC3 as a Novel Biomarker and Driver of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Progression.2026Annals of surgical oncology
  2. Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription.2026Applied biochemistry and biotechnology
  3. TMX1 promotes the progression of hepatocellular carcinoma by inhibiting ferroptosis via stabilizing FABP5.2026Cellular signalling
  4. Targeted delivery of IFN-α-anti-GPC3 fusion protein via mRNA-LNP platform elicits potent anti-tumor immunity in hepatocellular carcinoma.2026Drug delivery and translational research
  5. PLAUR+ Neutrophils Drive Anti-PD-1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. m6A methylation-mediated lncRNA RNF144A-AS1 promotes hepatocellular carcinoma progression through the miR-1301-3p/RNF38 pathway.2025Biology directFree full text
  7. L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity.2025Biology directFree full text
  8. HOXB4/METTL7B cascade mediates malignant phenotypes of hepatocellular carcinoma through TKT m6A modification.2025Biology directFree full text
  9. Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  11. Targeting YBX1-m5C mediates RNF115 mRNA circularisation and translation to enhance vulnerability of ferroptosis in hepatocellular carcinoma.2025Clinical and translational medicineFree full text
  12. LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression.2025Current cancer drug targets
  13. Single-cell sequencing and machine learning reveal the role of dioxin-interacting genes in HCC prognosis and immune microenvironment.2025Ecotoxicology and environmental safety
  14. Current research of the Notch pathway in hepatocellular carcinoma.2025European journal of medical researchFree full text
  15. An immune cell activation signature reflected hepatocellular carcinoma heterogeneity and predicted clinical outcomes.2025Frontiers in immunologyFree full text
  16. Integrated multi-omics analysis and machine learning refine molecular subtypes and prognosis in hepatocellular carcinoma through O-linked glycosylation genes.2025Functional & integrative genomics
  17. HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma.2025Hepatology communicationsFree full text
  18. ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy.2025International journal of nanomedicineFree full text
  19. Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC.2025Journal of gastroenterology and hepatology
  20. Programmed cell death-related genes define distinct molecular subtypes and risk profiles in hepatocellular carcinoma.2025Scientific reportsFree full text
  21. The EZ-ALBI and PALBI scores contribute to the clinical application of ALBI in predicting postoperative recurrence of HCC.2025Scientific reportsFree full text
  22. BRD4 interacting genes as prognostic biomarkers in hepatocellular carcinoma for optimized treatment strategies.2025Scientific reportsFree full text
  23. Prediction of microvascular invasion in hepatocellular carcinoma using a preoperative serum C-reactive protein-based nomogram.2025Scientific reportsFree full text
  24. In Situ Nanofiber Patch Boosts Postoperative Hepatocellular Carcinoma Immune Activation by Trimodal Combination Therapy.2024ACS nanoFree full text
  25. Differentiation of confluent hepatic fibrosis and infiltrative hepatocellular carcinoma on MR imaging.2024Abdominal radiology (New York)
  26. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma.2024BMC cancerFree full text
  27. Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma.2024BMC cancerFree full text
  28. Ferroptosis-related lncRNA NRAV affects the prognosis of hepatocellular carcinoma via the miR-375-3P/SLC7A11 axis.2024BMC cancerFree full text
  29. Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma.2024Biology directFree full text
  30. Analytical and Diagnostic Performance of a Dual-Target Blood Detection Test for Hepatocellular Carcinoma.2024Cancer reports (Hoboken, N.J.)Free full text
  31. Arachidonic acid metabolism CYP450 pathway is deregulated in hepatocellular carcinoma and associated with microvascular invasion.2024Cell biology international
  32. NFKBIZ regulates NFκB signaling pathway to mediate tumorigenesis and metastasis of hepatocellular carcinoma by direct interaction with TRIM16.2024Cellular and molecular life sciences : CMLSFree full text
  33. The role of abnormal ubiquitination in hepatocellular carcinoma pathology.2024Cellular signalling
  34. USP24 promotes autophagy-dependent ferroptosis in hepatocellular carcinoma by reducing the K48-linked ubiquitination of Beclin1.2024Communications biologyFree full text
  35. Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.2024Drug delivery and translational research
  36. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma.2024EpigeneticsFree full text
  37. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.2024European radiologyRCT
  38. A Predictive Model Based on the FBXO Family Reveals the Significance of Cyclin F in Hepatocellular Carcinoma.2024Frontiers in bioscience (Landmark edition)
  39. Development of a prognostic scoring system for hepatic vena cava Budd-Chiari syndrome with hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  40. Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE.2024Hepatology communicationsFree full text
  41. Delivery of SiRNA-PD-L1 by attenuated Salmonella in combination with oxaliplatin in a hepatocellular carcinoma mouse model.2024International immunopharmacology
  42. SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma.2024International immunopharmacology
  43. MARCH5 promotes hepatocellular carcinoma progression by inducing p53 ubiquitination degradation.2024Journal of cancer research and clinical oncologyFree full text
  44. Integrated Exploration of Epigenetic Dysregulation Reveals a Stemness/EMT Subtype and MMP12 Linked to the Progression and Prognosis in Hepatocellular Carcinoma.2024Journal of proteome research
  45. BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling.2024Molecular medicine (Cambridge, Mass.)Free full text
  46. Targeted immune cell therapy for hepatocellular carcinoma using expanded liver mononuclear cell-derived natural killer cells.2024Neoplasia (New York, N.Y.)Free full text
  47. NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma.2024Oncogene
  48. DNA methylation and gene expression profiling reveal potential association of retinol metabolism related genes with hepatocellular carcinoma development.2024PeerJFree full text
  49. Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein.2024PloS oneFree full text
  50. Deficiency of betaine-homocysteine methyltransferase activates glucose-6-phosphate dehydrogenase (G6PD) by decreasing arginine methylation of G6PD in hepatocellular carcinogenesis.2024Science China. Life sciences
  51. Single-cell transcriptomics reveals over-activated reactive oxygen species pathway in hepatocytes in the development of hepatocellular carcinoma.2024Scientific reportsFree full text
  52. Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma.2024Scientific reportsFree full text
  53. FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53/HK2 axis.2024Scientific reportsFree full text
  54. Multi-omic analysis identifies the molecular mechanism of hepatocellular carcinoma with cirrhosis.2024Scientific reportsFree full text
  55. Novel molecular hepatocellular carcinoma subtypes and RiskScore utilizing apoptosis-related genes.2024Scientific reportsFree full text
  56. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicent2024Signal transduction and targeted therapyRCTFree full text
  57. Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization.2023Academic radiologyRCT
  58. Classification of Signature-Based Phenotypes of Aging-Related Genes to Identify Prognostic and Immune Characteristics in HCC.2023Analytical cellular pathology (Amsterdam)Free full text
  59. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.2023BMC cancerFree full text
  60. Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma.2023BMC cancerFree full text
  61. TACE sequential MWA guided by cone-beam computed tomography in the treatment of small hepatocellular carcinoma under the hepatic dome.2023BMC cancerFree full text
  62. Comprehensive analysis of candidate signatures of long non-coding RNA LINC01116 and related protein-coding genes in patients with hepatocellular carcinoma.2023BMC gastroenterologyFree full text
  63. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.2023Cancer biology & therapyFree full text
  64. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  65. Homologous cancer cell membrane-camouflaged nanoparticles target drug delivery and enhance the chemotherapy efficacy of hepatocellular carcinoma.2023Cancer letters
  66. AARS2 as a novel biomarker for prognosis and its molecular characterization in pan-cancer.2023Cancer medicineFree full text
  67. Oncogenic pathways refine a new perspective on the classification of hepatocellular carcinoma.2023Cellular signalling
  68. The prognosis and clinicopathological significance of histone deacetylase in hepatocellular carcinoma: a meta-analysis.2023Clinical and experimental medicine
  69. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.2023Clinical and experimental medicine
  70. Implications of pseudogenes for the prognosis of hepatocellular carcinoma.2023Clinical and translational medicineFree full text
  71. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.2023Clinics and research in hepatology and gastroenterology
  72. DTL is a Novel Downstream Gene of E2F1 that Promotes the Progression of Hepatocellular Carcinoma.2023Current cancer drug targets
  73. Letter to the editor regarding "PET imaging of hepatocellular carcinoma by targeting tumor‑associated endothelium using [68 Ga]Ga‑PSMA‑617".2023European journal of nuclear medicine and molecular imaging
  74. Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.2023Frontiers in immunologyFree full text
  75. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  76. Deubiquitinating enzyme Josephin-2 stabilizes PHGDH to promote a cancer stem cell phenotype in hepatocellular carcinoma.2023Genes & genomics
  77. NSUN2-mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma.2023Genomics, proteomics & bioinformaticsFree full text
  78. The latest research progress on minimally invasive treatments for hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  79. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.2023Hepatology internationalFree full text
  80. TACC3 is an independent prognostic marker, and knockdown of TACC3 enhances the efficacy of CDK1 inhibitor RO3306 in liver cancer cells.2023Journal of biochemical and molecular toxicology
  81. Clinical Outcomes of Drug-eluting Beads Transarterial Chemoembolization for Unresectable Gastric Carcinoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  82. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues.2023Journal of translational medicineFree full text
  83. m6 A reader YTHDF3 triggers the progression of hepatocellular carcinoma through the YTHDF3/m6 A-EGFR/STAT3 axis and EMT.2023Molecular carcinogenesis
  84. LATS-regulated nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition.2023Molecular carcinogenesis
  85. SUMOylation of RNF146 results in Axin degradation and activation of Wnt/β-catenin signaling to promote the progression of hepatocellular carcinoma.2023Oncogene
  86. Comment on: Alnustone inhibits the growth of hepatocellular carcinoma via reactive oxygen species-mediated PI3K/Akt/mTOR/p70S6K axis.2023Phytotherapy research : PTR
  87. Identification and validation of candidate clinical signatures of apolipoprotein L isoforms in hepatocellular carcinoma.2023Scientific reportsFree full text
  88. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.2023Scientific reportsFree full text
  89. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.2023Scientific reportsFree full text
  90. Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.2023The international journal of biochemistry & cell biology
  91. Circ_0073228 serves as a competitive endogenous ribonucleic acid to facilitate proliferation and inhibit apoptosis of hepatocellular carcinoma cells by the miR-139-5p/deoxyribonuclease II axis.2023The journal of gene medicine
  92. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.2022BMC cancerFree full text
  93. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.2022BMC cancerFree full text
  94. GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  95. Circular RNA circ_0001955 promotes hepatocellular carcinoma tumorigenesis by up-regulating alkaline ceramidase 3 expression through microRNA-655-3p.2022BioengineeredFree full text
  96. The role of NCAPG in various of tumors.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  97. LINC00958: A promising long non-coding RNA related to cancer.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  98. A hypoxia-related prognostic model predicts overall survival and treatment response in hepatocellular carcinoma.2022Bioscience reportsFree full text
  99. Single-cell transcriptomics analysis reveals intratumoral heterogeneity and identifies a gene signature associated with prognosis of hepatocellular carcinoma.2022Bioscience reportsFree full text
  100. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.2022Canadian journal of gastroenterology & hepatologyFree full text
  101. CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex.2022Cancer gene therapy
  102. Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities.2022Cancer letters
  103. Fluid shear stress induces cell migration via RhoA-YAP1-autophagy pathway in liver cancer stem cells.2022Cell adhesion & migrationFree full text
  104. Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC.2022Cell death & diseaseFree full text
  105. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.2022Clinics and research in hepatology and gastroenterology
  106. Congenital intrahepatic portosystemic shunt with invasive hepatocellular carcinoma.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  107. Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma.2022Disease markersFree full text
  108. Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.2022Drug design, development and therapyFree full text
  109. Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells.2022Drug metabolism and disposition: the biological fate of chemicalsFree full text
  110. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.2022Frontiers in endocrinologyFree full text
  111. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  112. Analysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-seq.2022Frontiers in immunologyFree full text
  113. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.2022Frontiers in immunologyFree full text
  114. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  115. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  116. Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  117. A Novel m1A-Score Model Correlated With the Immune Microenvironment Predicts Prognosis in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  118. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  119. Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma.2022International immunopharmacology
  120. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.2022International immunopharmacology
  121. 3.0-T closed MR-guided microwave ablation for HCC located under the hepatic dome: a single-center experience.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  122. Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value.2022Journal of cancer research and clinical oncologyFree full text
  123. Endoplasmic Reticulum Stress-Related Signature for Predicting Prognosis and Immune Features in Hepatocellular Carcinoma.2022Journal of immunology researchFree full text
  124. Study on the Prognostic Values of TTC36 Correlated with Immune Infiltrates and Its Methylation in Hepatocellular Carcinoma.2022Journal of immunology researchFree full text
  125. Combined Chemoembolization with Iodine-125 Seed Implantation for the Treatment of an Oromaxillary Carcinoma: A Case Report.2022Journal of vascular and interventional radiology : JVIR
  126. Drug-Eluting Embolics Chemoembolization for the Management of Recurrent or Advanced Head and Neck Cancer.2022Journal of vascular and interventional radiology : JVIR
  127. LncCDCA3L inhibits cell proliferation via a novel RNA structure-based crosstalk with CDCA3 in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  128. SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.2022Oncology reportsFree full text
  129. A novel classification of HCC basing on fatty-acid-associated lncRNA.2022Scientific reportsFree full text
  130. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.2022Scientific reportsFree full text
  131. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.2022Scientific reportsFree full text
  132. Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders.2022Scientific reportsFree full text
  133. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.2022Scientific reportsFree full text
  134. Clinical observation of transcatheter arterial chemoembolization in super-aged patients with advanced gastric cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  135. PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway.2022Toxicology and applied pharmacology
  136. RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/β-catenin signalling pathways in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  137. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.2022World journal of surgical oncologyFree full text
  138. Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer.2021Abdominal radiology (New York)
  139. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer.2021Abdominal radiology (New York)
  140. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures.2021Academic radiology
  141. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1.2021AgingFree full text
  142. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.2021AgingFree full text
  143. Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer af2021Annals of palliative medicine
  144. Comment on Regarding Manuscript "Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis".2021Annals of surgery
  145. MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?2021BMC cancerFree full text
  146. Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance?2021BMC cancerFree full text
  147. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.2021BMC gastroenterologyFree full text
  148. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network.2021Bioscience reportsFree full text
  149. Down-regulation of RBP4 indicates a poor prognosis and correlates with immune cell infiltration in hepatocellular carcinoma.2021Bioscience reportsFree full text
  150. Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma.2021Canadian journal of gastroenterology & hepatologyFree full text
  151. Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma-A Propensity Analysis.2021Cardiovascular and interventional radiology
  152. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  153. Ultrasound-guided percutaneous metal-organic frameworks based codelivery system of doxorubicin/acetazolamide for hepatocellular carcinoma therapy.2021Clinical and translational medicineFree full text
  154. Predicting postoperative liver cancer death outcomes with machine learning.2021Current medical research and opinion
  155. LncRNA miR503HG inhibits epithelial-mesenchymal transition and angiogenesis in hepatocellular carcinoma by enhancing PDCD4 via regulation of miR-15b.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  156. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma.2021Future oncology (London, England)
  157. hMex-3A is associated with poor prognosis and contributes to the progression of hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  158. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.2021International immunopharmacology
  159. Enhancement of interferon gamma stability as an anticancer therapeutic protein against hepatocellular carcinoma upon interaction with calycosin.2021International journal of biological macromolecules
  160. Making timely remedial measures after TACE based on the results of cone-beam CT liver perfusion.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  161. High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
  162. Screening Prognosis-Related lncRNAs Based on WGCNA to Establish a New Risk Score for Predicting Prognosis in Patients with Hepatocellular Carcinoma.2021Journal of immunology researchFree full text
  163. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.2021Journal of translational medicineFree full text
  164. MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases.2021Laboratory medicine
  165. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1.2021Pharmacological research
  166. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.2021PloS oneFree full text
  167. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.2021Scientific reportsFree full text
  168. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.2021Scientific reportsFree full text
  169. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.2021The Journal of steroid biochemistry and molecular biology
Chinese-language papers (not in the count)4
  1. [Effect and mechanism of tigecycline on proliferation of liver tumor cells in mouse model].2025Zhonghua yi xue za zhi
  2. [Efficacy analysis of hepatic arterial infusion chemotherapy combined with targeted and immune therapy followed by 125I seeds implantation in the treatment of hepatocellular carcinoma with portal vain tumor thrombus].2024Zhonghua yi xue za zhi
  3. [Analysis of curative effects of chemoembolization with drug-loaded microspheres of different particle sizes for the treatment of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Safety and efficacy of cryoablation versus radiofrequency ablation for stage Ⅰ non-small-cell lung cancer].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status24
  1. A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence RiskRecruitingNCT06930573Lead sponsorPhase 4Start 2024-12
  2. Novel Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT03950518Lead sponsorPhase 3Start 2019-04
  3. Treatment of Intermediate-stage Hepatocellular CarcinomaStatus unknownNCT03274427Lead sponsorPhase 3Start 2017-07
  4. Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT03278444Lead sponsorPhase 3Start 2017-07
  5. A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Lead (inferred)Phase 4Start 2026-08
  6. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  7. A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingNCT07156617Study siteStart 2025-10
  8. A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAICNot yet recruitingNCT06823050Study siteStart 2025-03
  9. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  10. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  11. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  12. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  13. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  14. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  15. A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingNCT05155189Study sitePhase 1Start 2022-02
  16. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  17. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  18. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma PatientsStatus unknownNCT05343832Study siteStart 2021-11
  19. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  20. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  21. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  22. Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Study sitePhase 1Start 2019-08
  23. Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesStatus unknownNCT03638206Study sitePhase 1/Phase 2Start 2018-03
  24. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 105 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
105
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 191920212022: 131320222023: 262620232024: 252520242025: 18182025

4 hospitals in Zhengzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07294664

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  2. Recruiting
    A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07770113

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 1 listed hospital as study siteLuoyang, Zhengzhou

  3. Recruiting
    Energy CT in Imaging and Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06869694

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  4. Not yet recruiting
    IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07361991

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  5. Not yet recruiting
    RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  6. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  7. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  8. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  9. Recruiting
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07102901

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  10. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  11. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  12. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  13. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  14. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  15. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  16. Recruiting
    a Single-arm, Single-center, Open Clinical Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT06431100

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  17. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led105
  1. Photo-triggered engineered microbes achieving dual epigenetic immunomodulation for gastric cancer.2026Biomaterials
  2. Interpretable machine learning model using dual-energy CT for predicting adverse histopathological status in gastric cancer: A multicenter study.2026European journal of radiology
  3. Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study.2026European radiology
  4. m6A-Modified BASP1 Regulates IL6 Expression to Induce TAM Infiltration to Promote Gastric Cancer Progression.2026Journal of gastroenterology and hepatology
  5. CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.2025Academic radiology
  6. WSGC@FA@PEG/PEI-SPIONs Mitigate Chemoresistance in Gastric Adenocarcinoma by Modulating the Notch Signaling Pathway and Mitophagy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  7. Long transparent cap-assisted clip closure technique: a new choice for gastrointestinal defect closure.2025BMC gastroenterologyFree full text
  8. Construction and validation of a novel nomogram based on the log odds of positive lymph nodes to predict cancer-specific survival in elderly patients with gastric adenocarcinoma after radical surgery.2025BMC gastroenterologyFree full text
  9. Development of a nomogram for the prediction of postoperative survival in hepatoid adenocarcinoma of the stomach.2025Carcinogenesis
  10. Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3/HNF4A/TYMS axis.2025Cell death & diseaseFree full text
  11. PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer.2025Cellular signalling
  12. Longitudinal changes in tumor morphology and body composition following neoadjuvant chemotherapy predict progression-free survival in adenocarcinoma of the esophagogastric junction: A multi-center study.2025European journal of radiology
  13. Radiomics analysis of dual-energy CT-derived iodine maps for differentiating between T1/2 and T3/4a in gastric cancer: A multicenter study.2025European journal of radiology
  14. Dual-energy CT for predicting progression-free survival of locally advanced gastric cancer after gastrectomy: Insights into tumor angiogenesis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  15. Pygo2+ T cells possess immunosuppressive features and inferior immunotherapeutic response in gastric cancer.2025Frontiers in immunologyFree full text
  16. Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors.2025Frontiers in immunologyFree full text
  17. Clinical and pathological characteristics and treatment of gastric cancer during pregnancy.2025Indian journal of cancer
  18. Transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization for advanced gastric fundus and cardia cancer with obstruction.2025Journal of cancer research and clinical oncologyFree full text
  19. [Expression of Concern] Combination of the FGFR4 inhibitor PD173074 and 5‑fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.2025Oncology reportsFree full text
  20. Ailanthone targets mitophagy-loaded SIRT4 to facilitate the deacetylation of HIF1α, triggering oxidative stress for gastric carcinoma treatment.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  21. A signature based on efferocytosis-related genes for the evaluation of prognosis and the tumour microenvironment in gastric cancer.2025Scientific reportsFree full text
  22. Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.2025World journal of gastroenterologyFree full text
  23. The short peptide encoded by long non-coding RNA RNF217-AS1 inhibits stomach cancer tumorigenesis, macrophage recruitment, and pro-inflammatory responses.2024Amino acidsFree full text
  24. Gastric-type adenocarcinoma of the uterine cervix: A case report.2024Asian journal of surgery
  25. A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.2024BMC cancerFree full text
  26. Pomiferin targeting SLC9A9 based on histone acetylation modification pattern is a potential therapeutical option for gastric cancer with high malignancy.2024Biochemical pharmacology
  27. Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma.2024Cancer medicineFree full text
  28. miR-1304 targets KLK11 to regulate gastric cancer cell proliferation through the mTOR signaling pathway.2024Carcinogenesis
  29. POU6F1 promotes ferroptosis by increasing lncRNA-CASC2 transcription to regulate SOCS2/SLC7A11 signaling in gastric cancer.2024Cell biology and toxicologyFree full text
  30. TGF-β-driven LIF expression influences neutrophil extracellular traps (NETs) and contributes to peritoneal metastasis in gastric cancer.2024Cell death & diseaseFree full text
  31. Endoscopic resection of extra-luminal gastric gastrointestinal stromal tumors using a snare assisted external traction technique (with video).2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  32. Gastric adenocarcinoma of fundic gland type.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  33. Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors.2024Digestive diseases and sciences
  34. Easy and Feasible Closure for a Large Perforation After Gastric Full-Thickness Resection: Clipping Method with Symmetrical Anchors.2024Digestive diseases and sciences
  35. Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.2024Drug delivery and translational research
  36. Downregulation of short-stature homeobox protein 2 suppresses gastric cancer cell growth and stemness in vitro and in vivo via inactivating wnt/β-catenin signaling.2024Drug development research
  37. Downregulation of HIGD1B induces mitochondria-mediated apoptosis in gastric cancer cells by inactivating Akt and ERK pathways.2024Drug development research
  38. Multiple snares-assisted endoscopic full-thickness resection of a giant submucosal tumor at the esophagogastric junction.2024EndoscopyFree full text
  39. A dual-gene panel of two fragments of methylated IRF4 and one of ZEB2 in plasma cell-free DNA for gastric cancer detection.2024EpigeneticsFree full text
  40. Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer.2024European journal of medicinal chemistry
  41. Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.2024Frontiers in immunologyFree full text
  42. Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.2024Frontiers in immunologyFree full text
  43. CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer.2024International immunopharmacology
  44. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer.2024International journal of biological macromolecules
  45. Preoperative prediction of microvascular/nerve invasion in locally advanced gastric cancer by differentiation and enhanced CT features.2024MedicineFree full text
  46. The expression and clinical significance of serine hydroxymethyltransferase2 in gastric cancer.2024PeerJFree full text
  47. Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis.2024Scientific reportsFree full text
  48. Analysis of influencing factors of nerve invasion in locally advanced gastric cancer.2023Abdominal radiology (New York)
  49. A rare case of gastric schwannoma resection complicating by multiorgan high-frequency electrical burns.2023Asian journal of surgery
  50. Tumor lost in the oral cavity during the removal process: A rare complication of endoscopic submucosal excavation.2023Asian journal of surgery
  51. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.2023BMC gastroenterologyFree full text
  52. Predicting postoperative gastric cancer prognosis based on inflammatory factors and machine learning technology.2023BMC medical informatics and decision makingFree full text
  53. Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort.2023Cancer medicineRCT
  54. microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells.2023Cell biology and toxicology
  55. Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253.2023Cell cycle (Georgetown, Tex.)Free full text
  56. Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer.2023Clinical epigeneticsFree full text
  57. Identifying mitophagy-related genes as prognostic biomarkers and therapeutic targets of gastric carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data.2023Computers in biology and medicine
  58. Endoscopic full-thickness resection preserving the mucosa: more is better.2023EndoscopyFree full text
  59. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features.2023European journal of radiology
  60. Efficacy analysis of endoscopic treatment of giant gastric gastrointestinal stromal tumors (≥5 cm).2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  61. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.2023Frontiers in immunologyFree full text
  62. Comprehensive analysis of immune-related lncRNAs and their clinical relevance in gastric adenocarcinoma.2023Functional & integrative genomics
  63. Is it time for the adoption of same-day discharge after endoscopic submucosal dissection?2023Gastrointestinal endoscopy
  64. The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder Cancer: A Meta-Analysis.2023Genetic testing and molecular biomarkers
  65. Predictive value of platelet-to-lymphocyte ratio combined with CA199 levels in postoperative survival of patients with gastric cancer: A retrospective study.2023International immunopharmacology
  66. Survival influence of gender on 42,345 patients with gastric cardia adenocarcinoma.2023Journal of cancer research and clinical oncologyFree full text
  67. Prognostic value of blood lipids on patients treated with oxaliplatin combined with S-1 (SOX) after radical gastrectomy and establishment of prognostic nomogram.2023Journal of cancer research and clinical oncologyFree full text
  68. FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer.2023Journal of experimental & clinical cancer research : CRFree full text
  69. Short-term efficacy of additional laparoscopic-assisted radical gastrectomy after non-curative endoscopic submucosal dissection for early gastric cancer.2023Langenbeck's archives of surgery
  70. Effects of proximal gastrectomy with narrow gastric tube anastomosis compared with total gastrectomy with Roux-en-Y anastomosis on upper gastric cancer.2023Langenbeck's archives of surgery
  71. Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer.2023Scientific reportsFree full text
  72. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.2023Scientific reportsFree full text
  73. Can visceral fat parameters based on computed tomography be used to predict occult peritoneal metastasis in gastric cancer?2023World journal of gastroenterologyFree full text
  74. Abnormal phenotype of Nrf2 is associated with poor prognosis through hypoxic/VEGF-A-Rap1b/VEGFR2 pathway in gastric cancer.2022AgingFree full text
  75. Computed tomography features and clinicopathological characteristics of gastric glomus tumor.2022BMC gastroenterologyFree full text
  76. From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer.2022Biochemical and biophysical research communications
  77. MIR4435-2HG: A newly proposed lncRNA in human cancer.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  78. EGR1-CCL2 Feedback Loop Maintains Epithelial-Mesenchymal Transition of Cisplatin-Resistant Gastric Cancer Cells and Promotes Tumor Angiogenesis.2022Digestive diseases and sciences
  79. Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  80. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.2022Frontiers in immunologyFree full text
  81. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer.2022Journal of experimental & clinical cancer research : CRFree full text
  82. Comparison of short-term surgical outcomes between complete mesenteric resection and traditional transhiatal laparoscopic surgery for Siewert type II/III esophagogastric junction adenocarcinoma.2022Langenbeck's archives of surgery
  83. Stratified analysis of multiple management of gastric cancer: A population-based study of incidence, mortality and DALY.2022MedicineFree full text
  84. Clinical observation of transcatheter arterial chemoembolization in super-aged patients with advanced gastric cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  85. Suppression of JNK/ERK dependent autophagy enhances Jaspine B derivative-induced gastric cancer cell death via attenuation of p62/Keap1/Nrf2 pathways.2022Toxicology and applied pharmacology
  86. Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients.2022World journal of surgical oncologyFree full text
  87. TCGA-TCIA-Based CT Radiomics Study for Noninvasively Predicting Epstein-Barr Virus Status in Gastric Cancer.2021AJR. American journal of roentgenology
  88. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer.2021AJR. American journal of roentgenology
  89. Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer.2021AgingFree full text
  90. Praja2 suppresses the growth of gastric cancer by ubiquitylation of KSR1 and inhibiting MEK-ERK signal pathways.2021AgingFree full text
  91. The inhibitory effect of human DEFA5 in growth of gastric cancer by targeting BMI1.2021Cancer scienceFree full text
  92. Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment.2021European journal of medicinal chemistry
  93. Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.2021European journal of medicinal chemistry
  94. Radiomics analysis of CT imaging for differentiating gastric neuroendocrine carcinomas from gastric adenocarcinomas.2021European journal of radiology
  95. Elevated linc00936 or silenced microRNA-425-3p inhibits immune escape of gastric cancer cells via elevation of ZC3H12A.2021International immunopharmacology
  96. Inhibiting the JNK/ERK signaling pathway with geraniol for attenuating the proliferation of human gastric adenocarcinoma AGS cells.2021Journal of biochemical and molecular toxicology
  97. Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression.2021Journal of cellular and molecular medicineFree full text
  98. miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway.2021Journal of clinical laboratory analysisFree full text
  99. Bcl-2-associated transcription factor 1 Ser290 phosphorylation mediates DNA damage response and regulates radiosensitivity in gastric cancer.2021Journal of translational medicineFree full text
  100. CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage.2021Molecular medicine reportsFree full text
  101. Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma.2021Nature communicationsFree full text
  102. Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration.2021Oncology reportsFree full text
  103. Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.2021Phytotherapy research : PTRFree full text
  104. A machine learning-based predictor for the identification of the recurrence of patients with gastric cancer after operation.2021Scientific reportsFree full text
  105. Machine learning predicts lymph node metastasis of poorly differentiated-type intramucosal gastric cancer.2021Scientific reportsFree full text
Chinese-language papers (not in the count)4
  1. [The clinical characteristics of metastatic tumors in small intestine].2024Zhonghua yi xue za zhi
  2. [Influence of Psychological Factors on the Quality of Life of Patients with Non-surgical Gastric Cancer].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Diagnostic efficacy of a combined diagnostic model based on extreme gradient boosting algorithm in differentiating the pathological grading of gastric neuroendocrine neoplasms].2021Zhonghua yi xue za zhi
  4. [Expression of hepatocyte nuclear factor 4γ in gastric carcinoma and its role in cell proliferation and stemness].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status45
  1. IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Lead sponsorPhase 1/Phase 2Start 2026-03
  2. PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Lead sponsorPhase 2Start 2025-06
  3. A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingNCT07770113Lead sponsorPhase 2Start 2025-06
  4. RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Lead sponsorPhase 2Start 2024-07
  5. Energy CT in Imaging and Diagnosis of Gastric CancerRecruitingNCT06869694Lead sponsorStart 2024-09
  6. Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 StageStatus unknownNCT06194981Lead sponsorStart 2024-01
  7. A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) CancerStatus unknownNCT05241899Lead sponsorPhase 2Start 2022-05
  8. Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT05024812Lead sponsorPhase 1/Phase 2Start 2022-06
  9. Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGCStatus unknownNCT04819971Lead sponsorPhase 2Start 2021-12
  10. A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 ExpressionActive, not recruitingNCT06939452Lead (inferred)Phase 2Start 2023-06
  11. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  12. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  13. Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingNCT07102901Study sitePhase 2Start 2025-09
  14. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  15. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  16. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  17. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  18. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Study sitePhase 2Start 2024-10
  19. a Single-arm, Single-center, Open Clinical StudyRecruitingNCT06431100Study siteStart 2023-07
  20. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  21. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  23. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  24. Clinical Study of Pan-cancer DNA Methylation Test in PlasmaStatus unknownNCT05685524Study siteStart 2022-07
  25. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  26. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  28. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  29. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  30. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.TerminatedNCT05188209Study sitePhase 2Start 2021-12
  31. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  32. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  33. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  34. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  35. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  36. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  37. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  38. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  39. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  40. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  41. Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesStatus unknownNCT03638206Study sitePhase 1/Phase 2Start 2018-03
  42. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  43. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  44. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  45. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 2 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Zhengzhou for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicinePediatricsOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 5 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 2220242025: 002025

5 hospitals in Zhengzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led5
  1. Polydopamine-Based Targeted Nanosystem for Chemo/Photothermal Therapy of Retinoblastoma in a Mouse Orthotopic Model.2024International journal of nanomedicine
  2. Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis.2024The oncologist
  3. PRMT5 promotes retinoblastoma development.2023Human cell
  4. Long non-coding RNA XIST promotes retinoblastoma cell proliferation, migration, and invasion by modulating microRNA-191-5p/brain derived neurotrophic factor.2021Bioengineered
  5. microRNA-362-3p targets USP22 to retard retinoblastoma growth via reducing deubiquitination of LSD1.2021Cell cycle (Georgetown, Tex.)
Earlier papers (2016–2020)9
  1. Long noncoding RNA LINC00324 promotes retinoblastoma progression by acting as a competing endogenous RNA for microRNA-769-5p, thereby increasing STAT3 expression.2020Aging
  2. Carboplatin Inhibits the Progression of Retinoblastoma Through IncRNA XIST/miR-200a-3p/NRP1 Axis.2020Drug design, development and therapy
  3. Neferine induces mitochondrial dysfunction to exert anti-proliferative and anti-invasive activities on retinoblastoma.2020Experimental biology and medicine (Maywood, N.J.)
  4. Circular RNA (circ-0075804) promotes the proliferation of retinoblastoma via combining heterogeneous nuclear ribonucleoprotein K (HNRNPK) to improve the stability of E2F transcription factor 3 E2F3.2020Journal of cellular biochemistry
  5. SKP2, positively regulated by circ_ODC1/miR-422a axis, promotes the proliferation of retinoblastoma.2020Journal of cellular biochemistry
  6. MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. miR‑34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE‑A/p53 signaling.2019International journal of oncology
  8. LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells.2018Journal of cellular and molecular medicine
  9. miR106b regulates retinoblastoma Y79 cells through Runx3.2017Oncology reports

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Chinese-language papers (not in the count)1
  1. [Surgical techniques for the safe and rapid resection of primary or secondary sacral tumors located between the second and fourth sacral vertebrae].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)2
  1. A unique case of eyelid metastasis from chondroid chordoma.2019Indian journal of pathology & microbiology
  2. Differentiating skull base chordomas and invasive pituitary adenomas with conventional MRI.2018Acta radiologica (Stockholm, Sweden : 1987)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 34 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
34
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 111120212022: 6620222023: 8820232024: 5520242025: 442025

8 hospitals in Zhengzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPediatricsPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led34
  1. Mapping Knowledge Structure and Themes Trends of Ewing Sarcoma: A Text-Mining Study.2025Annals of surgical oncology
  2. NSUN2 promotes osteosarcoma metastasis via stabilizing UBE2S mRNA in an m5C-dependent manner.2025Cellular signalling
  3. Enhancing doxorubicin sensitivity in osteosarcoma via iRGD-modified biomimetic nanoparticles targeting MCAM m6A modification.2025Journal of translational medicine
  4. Menin inhibitor MI-503 exhibits potent anti-cancer activity in osteosarcoma.2025Scientific reports
  5. Primary intraspinal capicua transcriptional repressor-rearranged sarcoma with adjacent vertebral bone destruction: The imaging diagnostic clues.2024Asian journal of surgery
  6. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.2024Biology direct
  7. Inhibition of discoidin domain receptor 1 as a new therapeutic strategy for osteosarcoma.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  8. SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression.2024JCI insight
  9. Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.2024Journal of biochemical and molecular toxicology
  10. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.2023Aging
  11. HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth.2023Cell death & disease
  12. WTAP contributes to the tumorigenesis of osteosarcoma via modulating ALB in an m6A-dependent manner.2023Environmental toxicology
  13. Propofol Regulates ER Stress to Inhibit Tumour Growth and Sensitize Osteosarcoma to Doxorubicin.2023International journal of clinical practice
  14. Circ_001422 aggravates osteosarcoma progression through targeting miR-497-5p/E2F3 axis.2023Journal of biochemical and molecular toxicology
  15. A novel CircRNA Circ_0001722 regulates proliferation and invasion of osteosarcoma cells through targeting miR-204-5p/RUNX2 axis.2023Journal of cancer research and clinical oncology
  16. A short peptide LINC00665_18aa encoded by lncRNA LINC00665 suppresses the proliferation and migration of osteosarcoma cells through the regulation of the CREB1/RPS6KA3 interaction.2023PloS one
  17. Studying the mechanism underlying lipid metabolism in osteosarcoma based on transcriptomic RNA sequencing and single-cell data.2023The journal of gene medicine
  18. Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma.2022Bioengineered
  19. TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPM1D axis.2022Cell cycle (Georgetown, Tex.)
  20. Hypoxia inducible factor-3α promotes osteosarcoma progression by activating KDM3A-mediated demethylation of SOX9.2022Chemico-biological interactions
  21. A novel prognostic signature in osteosarcoma characterised from the perspective of unfolded protein response.2022Clinical and translational medicine
  22. Cellular nanomechanics derived from pattern-dependent focal adhesion and cytoskeleton to balance gene transfection of malignant osteosarcoma.2022Journal of nanobiotechnology
  23. The prognostic factors of Ewing sarcoma/peripheral primitive neuroectodermal tumor: A retrospective analysis of 67 patients at a single center.2022Medicine
  24. Downregulation of long non-coding RNA UCA1 represses tumorigenesis and metastasis of osteosarcoma via miR-513b-5p/E2F5 axis.2021Anti-cancer drugs
  25. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.2021Cancer medicine
  26. Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients.2021Cancer medicine
  27. Knockdown of MCM8 functions as a strategy to inhibit the development and progression of osteosarcoma through regulating CTGF.2021Cell death & disease
  28. Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‑330‑3p/PNN axis.2021International journal of molecular medicine
  29. Prognostic factors of chondroblastic osteosarcoma and nomogram development for prediction: A population-based, STROBE-compliant study.2021Medicine
  30. Clinical therapeutic effects of combined methotrexate and other chemotherapeutic agents in treating children and young patients with osteosarcoma: A protocol for systematic review and meta-analysis.2021Medicine
  31. Circular RNA hsa_circ_0032463 Acts as the Tumor Promoter in Osteosarcoma by Regulating the MicroRNA 498/LEF1 Axis.2021Molecular and cellular biology
  32. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.2021Pharmacological research
  33. Expression of immune-related genes as prognostic biomarkers for the assessment of osteosarcoma clinical outcomes.2021Scientific reports
  34. Down-regulation of circITCH promotes osteosarcoma development and resistance to doxorubicin via the miR-524/RASSF6 axis.2021The journal of gene medicine
Earlier papers (2016–2020)39
  1. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.2020Aging
  2. Upregulation of miRNA-154-5p prevents the tumorigenesis of osteosarcoma.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. Circular RNA_CNST Promotes the Tumorigenesis of Osteosarcoma Cells by Sponging miR-421.2020Cell transplantation
  4. Lung Metastasis Probability in Ewing Sarcoma: A Nomogram Based on the SEER Database.2020Current oncology (Toronto, Ont.)
  5. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.2020Journal of orthopaedic surgery and research
  6. [Clinical features and imaging analysis of primary bone lymphoma of the jaw].2020Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  7. Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p.2019Aging
  8. MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.2019Cancer medicine
  10. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis.2019Cell death & disease
  11. miR-671-5p Inhibits Tumor Proliferation by Blocking Cell Cycle in Osteosarcoma.2019DNA and cell biology
  12. Polyphyllin VI induces apoptosis and autophagy in human osteosarcoma cells by modulation of ROS/JNK activation.2019Drug design, development and therapy
  13. LncRNA ADPGK-AS1 regulated cell proliferation, invasion, migration and apoptosis via targeting miR-542-3p in osteosarcoma.2019European review for medical and pharmacological sciences
  14. Inhibitory effects of indirubin-3'-monoxime against human osteosarcoma.2019IUBMB life
  15. Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation.2019International journal of biological macromolecules
  16. lncRNA nuclear-enriched abundant transcript 1 promotes cell proliferation and invasion by targeting miR-186-5p/HIF-1α in osteosarcoma.2019Journal of cellular biochemistry
  17. miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.2019Journal of cellular biochemistry
  18. Inhibitory Effect of Sirtuin6 (SIRT6) on Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells.2019Medical science monitor : international medical journal of experimental and clinical research
  19. Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study.2019Medical science monitor : international medical journal of experimental and clinical research
  20. Prognosis of osteosarcomas in the mandible: 15-year experience of 55 patients.2019Medicine
  21. Identification of key genes in osteosarcoma by meta‑analysis of gene expression microarray.2019Molecular medicine reports
  22. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/β-catenin signaling pathway.2019The international journal of biochemistry & cell biology
  23. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.2018Biochimica et biophysica acta. Molecular basis of disease
  24. Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  25. miRNA-1284, a regulator of HMGB1, inhibits cell proliferation and migration in osteosarcoma.2018Bioscience reports
  26. SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway.2018Technology in cancer research & treatment
  27. RSF1 functions as an oncogene in osteosarcoma and is regulated by XIST/miR-193a-3p axis.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  28. Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells.2017Experimental cell research
  29. MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.2017Pathology, research and practice
  30. [Clinicopathologic analysis of Ewing-like BCOR-CCNB3 undifferentiated sarcoma].2017Zhonghua bing li xue za zhi = Chinese journal of pathology
  31. Fibulin-4 is a novel Wnt/β-Catenin pathway activator in human osteosarcoma.2016Biochemical and biophysical research communications
  32. Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.2016Biochemical and biophysical research communications
  33. MicroRNA-127-3p inhibits proliferation and invasion by targeting SETD8 in human osteosarcoma cells.2016Biochemical and biophysical research communications
  34. MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells.2016Oncology research
  35. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.2016Oncotarget
  36. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.2016Oncotarget
  37. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.2016Oncotarget
  38. Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  39. Primary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of Kidney with Caval Involvement in a Pregnant Woman.2016Urologia internationalis

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 8 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 5520242025: 112025

5 hospitals in Zhengzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led8
  1. Endoscopic versus laparoscopic resection of gastrointestinal stromal tumors at the esophagogastric junction using propensity score matching analysis.2025Scientific reports
  2. Endoscopic resection of extra-luminal gastric gastrointestinal stromal tumors using a snare assisted external traction technique (with video).2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  3. Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors.2024Digestive diseases and sciences
  4. Appendiceal fecalith misdiagnosed as cecal stromal tumor: don't fall into the trap.2024Endoscopy
  5. Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST).2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis.2024Scientific reportsFree full text
  7. Efficacy analysis of endoscopic treatment of giant gastric gastrointestinal stromal tumors (≥5 cm).2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  8. CTCF-activated SNHG16 facilitates gastrointestinal stromal tumor by targeting miR-128-3p/CASC3 axis.2022Experimental cell research
Earlier papers (2016–2020)6
  1. Diagnosis and Endoscopic Treatment of Gastrointestinal Stromal Tumors Arising from Esophagus.2020Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. [Gastrointestinal glomus tumors: a clinicopathological analysis of fifteen cases].2020Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. Endoscopic gastroplasty as therapy for postoperative gastric distortion and stenosis.2019Endoscopy
  4. Gastric heterotopic pancreas and stromal tumors smaller than 3 cm in diameter: clinical and computed tomography findings.2018Cancer imaging : the official publication of the International Cancer Imaging Society
  5. Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report.2017BMC cancer
  6. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.2017Oncotarget
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 15 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 1120232024: 4420242025: 662025

6 hospitals in Zhengzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurologyRadiation oncologyNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led15
  1. Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy.2025BMC cancer
  2. The Pattern of Anemia in Pediatric Solid Tumors Prior to and after Chemotherapy- A Retrospective Cohort Study.2025Current cancer drug targets
  3. Comprehensive assessment of the significance of cellular senescence-associated genes in neuroblastoma.2025Genes & genomics
  4. Multiomics Analysis Reveals Neuroblastoma Molecular Signature Predicting Risk Stratification and Tumor Microenvironment Differences.2025Journal of proteome research
  5. Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities.2025Journal of proteome research
  6. A non-invasive diagnostic approach for neuroblastoma utilizing preoperative enhanced computed tomography and deep learning techniques.2025Scientific reports
  7. Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study.2024Cellular signalling
  8. Development of Neuroprotective Agents for the Treatment of Alzheimer's Disease using Conjugates of Serotonin with Sesquiterpene Lactones.2024Current medicinal chemistry
  9. Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma.2024Genes & genomics
  10. Corydaline alleviates Parkinson's disease by regulating autophagy and GSK-3β phosphorylation.2024Psychopharmacology
  11. Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature.2023Journal of cancer research and clinical oncology
  12. LncRNA TUG1 compromised neuronal mitophagy in cerebral ischemia/reperfusion injury by targeting sirtuin 1.2022Cell biology and toxicology
  13. Phloretin enhances autophagy by impairing AKT activation and inducing JNK-Beclin-1 pathway activation.2022Experimental and molecular pathology
  14. Adipose-derived stem cell-derived extracellular vesicles inhibit neuroblastoma growth by regulating GABBR1 activity through LINC00622-mediated transcription factor AR.2022Journal of leukocyte biology
  15. Identification of Key Genes Associated with Risk and Prognosis of Neuroblastoma.2022Journal of molecular neuroscience : MN
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 31 cases of esthesioneuroblastoma].2021Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
Earlier papers (2016–2020)14
  1. Long non-coding RNA SNHG7 promotes neuroblastoma progression through sponging miR-323a-5p and miR-342-5p.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis.2020IUBMB life
  3. LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases.2019Cancer biology & therapy
  4. LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma.2019Cell cycle (Georgetown, Tex.)
  5. miR-34a inhibits progression of neuroblastoma by targeting autophagy-related gene 5.2019European journal of pharmacology
  6. Upregulated lncRNA small nucleolar RNA host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through miR-15b-5p/GSK3β axis in human dopaminergic SH-SY5Y cells.2019Journal of cellular biochemistry
  7. XRCC1 gene polymorphisms and risk of neuroblastoma in Chinese children.2018Aging
  8. Advances in the Surgical Treatment of Neuroblastoma.2018Chinese medical journal
  9. Anisomycin prevents OGD-induced necroptosis by regulating the E3 ligase CHIP.2018Scientific reports
  10. Neuroprotective effects of α-melanocyte-stimulating hormone against the neurotoxicity of 1-methyl-4-phenylpyridinium.2017IUBMB life
  11. Honokiol triggers receptor‑interacting protein kinase 3‑mediated cell death of neuroblastoma cells by upregulating reactive oxygen species.2017Molecular medicine reports
  12. Truncated apolipoprotein C-I induces apoptosis in neuroblastoma by activating caspases in the extrinsic and intrinsic pathways.2017Oncology reports
  13. 2,2',4,4'-Tetrabromodiphenyl ether promotes human neuroblastoma SH-SY5Y cells migration via the GPER/PI3K/Akt signal pathway.2016Human & experimental toxicology
  14. Polymorphisms of glucose-regulated protein 78 and clinical relevance of neuroblastoma: Risk and prognosis.2016Journal of cancer research and therapeutics

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 3 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

3 hospitals in Zhengzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 15 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.9%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 6620232024: 3320242025: 002025

4 hospitals in Zhengzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  3. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  4. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  5. Not yet recruiting
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06799676

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugsCAR-T & cell therapy
Departments in papersPathology / laboratory medicineMedical oncologyNeurology
Papers it led15
  1. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.2024BMJ openFree full text
  2. Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.2024Clinical and experimental medicineFree full text
  3. Quantitative Analysis of Whole-Body MRI for Accessing the Degree of Diffuse Infiltration Patterns and Identifying High Risk Cases of Newly Diagnosed Multiple Myeloma.2024Journal of magnetic resonance imaging : JMRI
  4. FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma.2023Cancer gene therapy
  5. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.2023Cancer medicineFree full text
  6. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.2023Expert opinion on biological therapy
  7. Long non‑coding RNAs in multiple myeloma (Review).2023International journal of oncologyFree full text
  8. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.2023Journal of hematology & oncologyFree full text
  9. Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma.2023Scientific reportsFree full text
  10. Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging.2022Academic radiology
  11. Chimeric antigen receptor T-cell therapy for multiple myeloma.2022Frontiers in immunologyFree full text
  12. Differentiation of Diffuse Infiltration Pattern in Multiple Myeloma From Hyperplastic Hematopoietic Bone Marrow: Qualitative and Quantitative Analysis Using Whole-Body MRI.2022Journal of magnetic resonance imaging : JMRI
  13. Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma.2021Leukemia research
  14. Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment.2021Leukemia research
  15. Multiple myeloma with Echinococcus granulosus infection diagnosed by detection of oligoclonal bands: A case report.2021MedicineFree full text
Chinese-language papers (not in the count)3
  1. [Expression of Interleukin-10 and Interleukin-15 in Patients with Multiple Myeloma and Its Clinical Significance].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies].2023Zhongguo shi yan xue ye xue za zhiRCT
  3. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Efficacy and Safety Evaluation of PD1-BCMA-CARTStatus unknownNCT05308875Lead (inferred)N/AStart 2024-03
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Study sitePhase 1/Phase 2Start 2025-02
  5. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  6. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  7. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  8. Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesStatus unknownNCT03638206Study sitePhase 1/Phase 2Start 2018-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Zhengzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
    Phase
    Phase 4
    Started
    2023-09
    Registry
    NCT06339775

    Age Not stated to 65 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  2. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06890065

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  3. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2023-09
    Registry
    NCT06678282

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  4. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantPhiladelphia chromosome & genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 9 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 2220232024: 1120242025: 112025

2 hospitals in Zhengzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07552506

    Age 14 years to 50 years; women only (registered criteria)

    Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantChildrenClonal evolution & PNH
Departments in papersPediatrics
Papers it led9
  1. Protective factors, management and prognosis of mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia in children.2025Bone marrow transplantation
  2. Unbiased Single-Cell Sequencing of Hematopoietic and Immune Cells from Aplastic Anemia Reveals the Contributors of Hematopoiesis Failure and Dysfunctional Immune Regulation.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.2023Clinical and experimental medicineFree full text
  4. Analysis of Mean Corpuscular Volume and Red Cell Distribution Width in Patients with Aplastic Anemia.2023Hemoglobin
  5. Very severe aplastic anemia with papillary thyroid carcinoma: treatment with allo-HSCT-a case report and literature review.2022Annals of hematology
  6. MiR-150-5p regulate T cell activation in severe aplastic anemia by targeting Bach2.2021Cell and tissue research
  7. Acute arrest of hemopoiesis presenting as severe aplastic anemia: a retrospective analysis.2021Hematology (Amsterdam, Netherlands)
  8. Decreased bone marrow regulatory innate lymphoid cells show a distinctive miRNA profiling in aplastic anemia.2021Hematology (Amsterdam, Netherlands)
  9. Hypermethylation-mediated downregulation of long non-coding RNA MEG3 inhibits osteogenic differentiation of bone marrow mesenchymal stem cells and promotes pediatric aplastic anemia.2021International immunopharmacology
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using GoserelinNot yet recruitingNCT07552506Study siteN/AStart 2026-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 3 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

1 hospital in Zhengzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersChildrenLymphoma & cancer-related HLH
Departments in papersPediatricsENT / head & neck surgeryMedical oncology
Papers it led3
  1. Case Report: Two cases of chronic active Epstein-Barr virus disease presenting as refractory sinusitis.2025Frontiers in immunologyFree full text
  2. Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection.2024Annals of hematology
  3. Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders.2024Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)1
  1. [Analysis of clinical phenotype and genetic variant in a case of familial hemophagocytic lymphohistiocytosis type Ⅲ].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status2
  1. A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Lead (inferred)Phase 4Start 2021-05
  2. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
More papers found outside PubMed (not counted)3
  1. Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study2025Bloodconference-abstract
  2. Cytokine Patterns for Secondary HLH: Experiences from a Single Center2024Bloodconference-abstract
  3. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)article

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhengzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Chinese-language papers (not in the count)1
  1. [Genotypic and hematological characteristics of 83 β-thalassemia mutation carriers and patients from Henan Province].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 3 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Zhengzhou for haemophilia A132 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led3
  1. Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation.2022Biochemical and biophysical research communications
  2. Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China.2021Haemophilia : the official journal of the World Federation of Hemophilia
  3. FVIII inhibitor risk correlated with F8 gene variants in 296 unrelated male Chinese patients with haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
Chinese-language papers (not in the count)1
  1. [Analysis of gene inversion in Hemophilia A by Nanopore sequencing].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)3
  1. Factor VIII mutation spectrum in haemophilia A patients in the population of Henan, China.2017Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  2. [Genetic analysis for a family affected with hemophilia type A due to a large deletion of F8 gene].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Detection and genetic counseling of F8 gene inversions for patients with severe hemophilia A].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Zhengzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 11 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.3%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 0020232024: 1120242025: 332025

2 hospitals in Zhengzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentImaging
Departments in papersNeurologyPediatrics
Papers it led11
  1. Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG.2025Frontiers in immunologyFree full text
  3. Biomarkers for diagnosis and prognosis of myelin oligodendrocyte glycoprotein antibody-associated disease - review article.2025Frontiers in immunologyFree full text
  4. Renal dysfunction in AQP4 NMOSD and MS; a potential predictor of relapse and prognosis.2024Clinical immunology (Orlando, Fla.)
  5. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders.2022Brain and behaviorFree full text
  6. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.2022Journal of neurology
  7. Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study.2021BMC neurologyFree full text
  8. Serum Immunoglobulin G Level and Neutrophils to Lymphocytes Ratio Associated with the Prognosis of Neuromyelitis Optica Spectrum Disorder.2021Current neurovascular research
  9. High Level of Serum and Cerebrospinal Fluid of Heparan Sulfate and Hyaluronic Acid Might Be a Biomarker of Severity of Neuromyelitis Optica.2021Frontiers in immunologyFree full text
  10. Association of Circulating Follicular Helper T Cells and Serum CXCL13 With Neuromyelitis Optica Spectrum Disorders.2021Frontiers in immunologyFree full text
  11. Impaired Meningeal Lymphatic Flow in NMOSD Patients With Acute Attack.2021Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  2. A Study of RD06-04 in Patients With Active Autoimmune DiseasesWithdrawnNCT06548620Study siteEarly phase 1Start 2024-08
  3. An Open Label Study of the Effects of SHR1459 in NMOSDs PatientsCompletedNCT04670770Study sitePhase 2Start 2021-01
More papers found outside PubMed (not counted)8
  1. A Real-world Study of Inebilizumab for Neuromyelitis Optica Spectrum Disorders (P9-1.008)2025Neurologyarticle
  2. Association of Roquin-1 and Tfh cells with Clinical Characteristic in Neuromyelitis Optica (P11-8.003)2025Neurologyarticle
  3. MALT1 Scaffold and Proteolytic Activity Regulate Tfh Cell Differentiation in the Progression of Neuromyelitis Optica (S38.002)2025Neurologyarticle
  4. Potential Correlation Between the Cuprotosis-Related Genes and Acute-Remitting Course in Neuromyelitis Optica Spectrum Disorder (P12-8.004)2025Neurologyarticle
  5. Progress on single-cell sequencing technology in central nervous system autoimmune diseases2025DOAJ (DOAJ: Directory of Open Access Journals)article
  6. Loss of Roquin-1 Enhances CXCR5+PD-1+ Tfh Cell Differentiation by Interfering with Ampkfunction to Enhance Glycolysis in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorders2024SSRN Electronic Journalpreprint
  7. Loss of Roquin-1 enhances CXCR5+PD-1+Tfh cell differentiation by interfere AMPK function to enhance glycolysis in Neuromyelitis Optica2024Research Squarepreprint
  8. Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases2021Neuroimmunology Reportsarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

3 hospitals in Zhengzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisStandard immunotherapy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 10 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.8%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 4420232024: 3320242025: 222025

2 hospitals in Zhengzhou for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  2. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersNeurosurgeryNeurologyPediatricsRadiology / nuclear medicine
Papers it led10
  1. Clinical characteristics and potential pathology of Moyamoya disease combined with psychiatric disorders in Chinese population - A cross-sectional study.2025Journal of affective disorders
  2. Development and validation of nomograms for aneurysm rupture risk and prognosis in Moyamoya disease with intracranial aneurysms.2025Scientific reportsFree full text
  3. Moyamoya syndrome secondary to hereditary spherocytosis: A case report.2024Asian journal of surgery
  4. Proteomics and digital subtraction angiography approaches reveal CDH18 as a potential target for therapy of moyamoya disease.2024Biology directFree full text
  5. Cerebral hemodynamic plasticity related to potential compensatory self-recirculation network in Moyamoya disease: an observational study.2024Scientific reportsFree full text
  6. Follow-up outcomes of different bypass surgical modalities for adults with ischaemic-type moyamoya disease.2023British journal of neurosurgery
  7. A Retrospective Study on Clinical Features of Childhood Moyamoya Disease.2023Pediatric neurology
  8. Risk factors for wound healing complications after revascularization for MMD with complete Y-shaped incision.2023Scientific reportsFree full text
  9. Analysis of Clinical Characteristic and Risk Factors for Short-Term Prognosis of Moyamoya Disease with Intraventricular Hemorrhage in Adults.2023World neurosurgery
  10. Clinical features of and risk factors for intracranial aneurysms associated with moyamoya disease.2021International journal of stroke : official journal of the International Stroke Society
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 15 pregnant women complicated with moyamoya disease].2023Zhonghua fu chan ke za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  2. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 1 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Zhengzhou for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Treatment (chelation, zinc)Children
Departments in papersNeurology
Papers it led1
  1. Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.2021Clinics and research in hepatology and gastroenterology
Chinese-language papers (not in the count)1
  1. [Genotype-phenotype relationship and genetics study of 115 cases with Wilson's disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 9 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 3.4%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 0020232024: 1120242025: 222025

6 hospitals in Zhengzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06867991

    Age 12 years to Not stated (registered criteria)

    Led by Third Affiliated Hospital of Soochow University; 1 listed hospital as study siteChangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led9
  1. Clinical characteristics and treatment of patients with overlapping MOG and anti-NMDAR encephalitis.2025BMC neurology
  2. The gut-brain axis: potential reshaping the future of anti-NMDAR encephalitis treatment.2025Frontiers in immunology
  3. Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Relapse factors of patients of anti-N-methyl-D-aspartate receptor encephalitis.2022Acta neurologica Scandinavica
  5. Brain magnetic resonance imaging predictors in anti-N-methyl-D-aspartate receptor encephalitis.2022Annals of clinical and translational neurology
  6. Neutrophil Percentage-to-Albumin Ratio: A Good Parameter for the Evaluation of the Severity of Anti-NMDAR Encephalitis at Admission and Prediction of Short-Term Prognosis.2022Frontiers in immunology
  7. Clinical and Radiological Characteristics of Children and Adults With First-Attack Myelin Oligodendrocyte Glycoprotein Antibody Disease and Analysis of Risk Factors for Predicting the Severity at Disease Onset in Central China.2021Frontiers in immunology
  8. Influential factors and predictors of anti-N-methyl-D-aspartate receptor encephalitis associated with severity at admission.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Emerging role of free triiodothyronine in patients with anti-N-methyl-D-aspartate receptor encephalitis.2021Scientific reports
Earlier papers (2016–2020)3
  1. A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies.2020BMC neurology
  2. Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. [Clinical analysis of anti-NMDA receptor encephalitis complicated by paroxysmal sympathetic hyperactivity].2016Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
All its trials on ClinicalTrials.gov, any status2
  1. Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisRecruitingNCT06867991Study sitePhase 3Start 2024-11
  2. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR AntibodiesNot yet recruitingNCT07858175Study siteStart 2026-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)2
  1. [Mid- and long-term results of surgical treatment of brachiocephalic Takayasu arteritis].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Effects of pregnancy complicated with Takayasu arteritis on maternal and fetal outcomes].2022Zhonghua fu chan ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Zhengzhou for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Multiple hepatic alveolar echinococcosis infestation.2024Asian journal of surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 332025

8 hospitals in Zhengzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led12
  1. Inhalable nanosystem promote in situ packaging of IL-11 antisense oligonucleotides into macrophage-derived vesicles for idiopathic pulmonary fibrosis.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Resveratrol improves idiopathic pulmonary fibrosis by targeting IKZF3.2026The Journal of nutritional biochemistry
  3. Single Cell RNA-Seq Identifies Cell Subpopulations Contributing to Idiopathic Pulmonary Fibrosis in Humans.2025Journal of cellular and molecular medicine
  4. The role of oxidative stress-related genes in idiopathic pulmonary fibrosis.2025Scientific reports
  5. Causal Effects Between Genetically Determined Human Serum Metabolite Levels on the Risk of Idiopathic Pulmonary Fibrosis: A Mendelian Randomization Study.2025The clinical respiratory journal
  6. ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target.2024Journal of translational medicine
  7. SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis.2024Journal of translational medicine
  8. Multicenter Population Pharmacokinetics and Exposure-Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.2023Clinical pharmacokinetics
  9. Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma.2023Pulmonary pharmacology & therapeutics
  10. Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway.2022International immunopharmacology
  11. Nitrative inactivation of thioredoxin-1 loses its protective effect in bleomycin-induced pulmonary fibrosis.2022International immunopharmacology
  12. Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials.2021BMJ open
Chinese-language papers (not in the count)1
  1. [Pulmonary artery stenosis after single lung transplantation: a case report and literature review].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)5
  1. CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting proliferation and activation of fibroblasts.2020Cell death & disease
  2. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].2020Zhonghua yi xue za zhi
  3. Knockdown of Long Noncoding RNA H19 Represses the Progress of Pulmonary Fibrosis through the Transforming Growth Factor β/Smad3 Pathway by Regulating MicroRNA 140.2019Molecular and cellular biology
  4. S100A4+ Macrophages Are Necessary for Pulmonary Fibrosis by Activating Lung Fibroblasts.2018Frontiers in immunology
  5. Role of thioredoxin nitration in bleomycin-induced pulmonary fibrosis in rats.2016Canadian journal of physiology and pharmacology
All its trials on ClinicalTrials.gov, any status4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  3. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  4. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhengzhou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Zhengzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06671236

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyENT / head & neck surgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Identification of two novel SMN1 point mutations associated with a very severe SMA-I phenotype.2020European journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Pseudo-dominant inheritance of a novel double GLA mutation associated with Fabry disease mimicking familial episodic pain.2016American journal of medical genetics. Part A
All its trials on ClinicalTrials.gov, any status1
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseStatus unknownNCT06114329Study sitePhase 2Start 2023-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhengzhou for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy DrugActive, not recruitingNCT05793307Study sitePhase 1/Phase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 6 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 2.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 222025

5 hospitals in Zhengzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led6
  1. Unexpected Findings of Duchenne Muscular Dystrophy in Prenatal Screening of Chromosome Abnormality Based on Cell-Free Fetal DNA.2025American journal of perinatology
  2. GsMTx4-blocked PIEZO1 channel promotes myogenic differentiation and alleviates myofiber damage in Duchenne muscular dystrophy.2025Skeletal muscle
  3. Prenatal diagnosis of 1408 foetuses at risk of DMD/BMD by MLPA and Sanger sequencing combined with STR linkage analysis.2023BMC medical genomics
  4. Noninvasive prenatal testing of Duchenne muscular dystrophy in a twin gestation.2022Prenatal diagnosis
  5. Noninvasive prenatal diagnosis of duchenne muscular dystrophy in five Chinese families based on relative mutation dosage approach.2021BMC medical genomics
  6. DMD/BMD prenatal diagnosis and treatment expectation in a single centre in China for 15 years.2021BMC medical genomics
Chinese-language papers (not in the count)4
  1. [Analysis of DMD gene variants in a single center].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Analysis of results of prenatal diagnosis for 67 pedigrees affected with Duchenne muscular dystrophy in the central plain region of China].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Diagnosis of a patient with adjacent gene deletion syndrome with DMD complete deletion type of Duchenne muscular dystrophy].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  4. [Variant analysis and therapeutic prospect for Chinese pedigrees affected with Duchenne/Becker muscular dystrophy from a single center over the past 15 years].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)7
  1. Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy.2019BMC medical genetics
  2. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.2019Human gene therapy methods
  3. [Application of next-generation sequencing in the molecular diagnosis of Duchenne muscular dystrophy].2019Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  4. [Two cases of rare diseases with abnormalities of X chromosome].2019Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  5. Generation of ZZUi008-A, a transgene-free, induced pluripotent stem cell line derived from chorionic villi cells of a fetus with Duchenne muscular dystrophy.2018Stem cell research
  6. [Mutation analysis of 81 cases with Duchenne/Becker muscular dystrophy].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  7. [Mutation screening of 433 families with Duchenne/Becker muscular dystrophy].2016Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 9 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 3.7%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 3320232024: 2220242025: 002025

2 hospitals in Zhengzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)5
  1. [Genetic testing and prenatal diagnosis for two Chinese pedigrees affected with Alport syndrome due to variants of COL4A5 gene].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. [Clinical and genetic analysis of a child with X-linked dominant Alport syndrome].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Genetic analysis of a patient with Alport syndrome due to compound heterozygous variants of COL4A4 gene].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  4. [Analysis of two Chinese pedigrees affected with Alport syndrome due to novel variants of COL4A5 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  5. [Genetic and clinical analysis of a pedigree affected with X-linked dominant Alport syndrome due to a novel variant of COL4A5 gene].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)1
  1. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique.2019Molecular genetics & genomic medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 35 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 4.8%.

Papers led
35
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 5520232024: 7720242025: 662025

3 hospitals in Zhengzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPediatricsPathology / laboratory medicine
Papers it led35
  1. The association between fractalkine/CX3CR1 axis with IgA vasculitis and nephritis.2026Pediatric research
  2. Yeast Cell Wall-Mediated Ileal Targeted Delivery System for IgA Nepharopathy Therapy.2025ACS biomaterials science & engineering
  3. The role of innate lymphoid cells in kidney disease.2025Cytokine & growth factor reviews
  4. Noninvasive prediction of T-score in IgA nephropathy using machine learning within the Oxford classification system.2025Frontiers in endocrinology
  5. Efficacy of methylprednisolone pulse therapy in Chinese children with IgA vasculitis-associated nephritis (IgAVN).2025Journal of nephrology
  6. Gut microbiota as a predictive tool for outcomes in IgA nephropathy.2025Renal failure
  7. Single nucleus RNA-seq reveals the process from onset to chronic kidney disease in IgA nephropathy.2025Scientific reports
  8. Differentiated metabolomic profiling reveals plasma amino acid signatures for primary glomerular disease.2024Amino acids
  9. External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort.2024Clinical and experimental nephrology
  10. Clinical features and prognosis of patients with anti-GBM disease combined with mesangial IgA deposition.2024Frontiers in immunology
  11. Genome-wide analysis of long noncoding RNAs as cis-acting regulators of transcription factor-encoding genes in IgA nephropathy.2024PloS one
  12. The prognostic value of the systemic immune inflammation index in patients with IgA nephropathy.2024Renal failure
  13. Novel immune cross-talk between inflammatory bowel disease and IgA nephropathy.2024Renal failure
  14. The transcription factor HMGB2 indirectly regulates APRIL expression and Gd-IgA1 production in patients with IgA nephropathy.2024Renal failure
  15. Mild mesangial proliferative IgA nephropathy with and without minimal change disease.2023Clinical and experimental medicine
  16. Telitacicept for autoimmune nephropathy.2023Frontiers in immunology
  17. Established the first clinical prediction model regarding the risk of hyperuricemia in adult IgA nephropathy.2023International urology and nephrology
  18. Role of abnormal glycosylated IgA1 and interstitial transformation of glomerular endothelial cells in the development and progression of IgA nephropathy.2023Italian journal of pediatrics
  19. Predictive prognostic value of glomerular C3 deposition in IgA nephropathy.2023Journal of nephrology
  20. Renal Megalin mRNA Downregulation Is Associated with CKD Progression in IgA Nephropathy.2022American journal of nephrology
  21. IgA nephropathy with acute kidney disease: Characteristics, prognosis, and causes.2022European journal of internal medicine
  22. Development and validation of diagnostic models for immunoglobulin A nephropathy based on gut microbes.2022Frontiers in cellular and infection microbiology
  23. Hyperuricemia aggravates the progression of IgA nephropathy.2022International urology and nephrology
  24. Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy.2022International urology and nephrology
  25. The predictive value of Oxford MEST-C classification to immunosuppressive therapy of IgA nephropathy.2022International urology and nephrology
  26. Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.2022International urology and nephrology
  27. The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov.2022Renal failure
  28. ICAM-1 related long noncoding RNA is associated with progression of IgA nephropathy and fibrotic changes in proximal tubular cells.2022Scientific reports
  29. Preliminary study on the application of renal ultrasonography radiomics in the classification of glomerulopathy.2021BMC medical imaging
  30. Overlapping obesity-related glomerulopathy and immunoglobulin A nephropathy: clinical and pathologic characteristics and prognosis.2021Clinical and experimental nephrology
  31. Elevated Serum Chloride Levels Contribute to a Poor Prognosis in Patients with IgA Nephropathy.2021Journal of immunology research
  32. Role of Human Mesangial-Tubular Crosstalk in Secretory IgA-Induced IgA Nephropathy.2021Kidney & blood pressure research
  33. Elevated Endostatin Expression Is Regulated by the pIgA Immune Complex and Associated with Disease Severity of IgA Nephropathy.2021Kidney & blood pressure research
  34. Normotensive and hypertensive Immunoglobulin a nephropathy with ischemic renal injury: clinicopathological characteristics and prognosis.2021Renal failure
  35. MicroRNAs in IgA nephropathy.2021Renal failure
Earlier papers (2016–2020)17
  1. External Validation of the International IgA Nephropathy Prediction Tool.2020Clinical journal of the American Society of Nephrology : CJASN
  2. The TLR4-MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy.2020Journal of nephrology
  3. The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy.2020PloS one
  4. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases.2020Scientific reports
  5. A non-invasive diagnostic model of immunoglobulin A nephropathy and serological markers for evaluating disease severity.2019Chinese medical journal
  6. Elevated hsa-miR-590-3p expression down-regulates HMGB2 expression and contributes to the severity of IgA nephropathy.2019Journal of cellular and molecular medicine
  7. High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy.2019Nephrology (Carlton, Vic.)
  8. [Clinical effect of tacrolimus combined with glucocorticoid in the treatment of IgA nephropathy in children].2019Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  9. Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy.2018American journal of physiology. Renal physiology
  10. Renal miR-148b is associated with megalin down-regulation in IgA nephropathy.2018Bioscience reports
  11. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.2018Journal of the American Society of Nephrology : JASN
  12. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy.2018Kidney & blood pressure research
  13. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.2017Clinical and experimental immunology
  14. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis.2017International urology and nephrology
  15. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.2017PloS one
  16. Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases.2016Diagnostic pathology
  17. MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients.2016Experimental cell research
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)2
  1. [Analysis of LRP5 gene variants in a Chinese pedigree affected with Osteoporosis-pseudoglioma syndrome].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. [Preimplantation genetic testing for a couple where the husband is affected by osteogenesis imperfecta combined with balanced translocation using karyomapping technique].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)3
  1. [Analysis of COL1A1 gene variants in five Chinese pedigrees affected with osteogenesis imperfecta].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. Solanum muricatum Ameliorates the Symptoms of Osteogenesis Imperfecta In Vivo.2019Journal of food science
  3. [Mutational analysis and prenatal diagnosis of COL1A1 and COL1A2 genes in four Chinese families affected with osteogenesis imperfecta].2017Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

2 hospitals in Zhengzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Analysis of a case with Mowat-Wilson syndrome due to nonsense variant of ZEB2 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 2 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 3.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Zhengzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

郑州大学第一附属医院

First Affiliated Hospital of Zhengzhou University

郑州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
first Affiliated Hospital of Zhengzhou University; Zhengzhou University First Affiliated Hospital

Suggest a correctionDownload the data